Harrow, Inc. reported first-quarter 2026 revenue for its VEVYE product at $20.9 million, below expectations due to an $8 million gross-to-net reduction linked to new commercial coverage. Following this announcement, Harrow's stock price fell 23.69% on May 12, 2026. The law firm Wohl & Fruchter LLP has launched an investigation into whether Harrow violated federal securities laws related to this revenue shortfall. Investors who suffered losses are encouraged to contact the firm for legal advice and potential action.
Cerebras Systems, an AI chip maker based in Sunnyvale, California, is set to go public on Nasdaq under the ticker CBRS on May 14, 2026, marking the first IPO from TSG Invest's Venture 50 Index. The company raised its IPO price range to $150-$160 per ...
Cerebras Systems, an AI chip maker known for its wafer-scale engine technology, is set to debut on Nasdaq under ticker CBRS, marking the first IPO from TSG Invest's Venture 50 Index. The company raised its IPO price range to $150-$160 per share due t...
Techstars has formed a strategic partnership with fintech platform Xendoo and accounting software Xero to offer startups a comprehensive financial operations solution. This collaboration aims to help early-stage companies maintain better financial vi...
Sapu Nano and Oncotelic have dosed the first patient in a Phase 1b clinical trial of Sapu003, an intravenous formulation of everolimus designed to treat advanced mTOR-sensitive solid tumors such as HR+/HER2- breast cancer and renal cell carcinoma. Th...
The Gabelli Utility Trust Board approved monthly cash distributions of $0.05 per share for July, August, and September 2026, maintaining its fixed monthly payout policy. The Fund's shares currently trade at a premium to net asset value, which the Boa...
